Highlights Oct 19 - Oct 25, 2026
new every Sunday
This week brought concrete movement on access and evaluation, from the VA's planned rollout and European pathways to ICER's review of COMP360. New controlled studies also clarified the safety and effects of prolonged DMT dosing and MDA.
-
01
Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Federal Officials Weigh In on Psychedelic Access
Federal officials detailed the VA's ten-site rollout, capacity constraints, and plans to collect real-world evidence on psychedelic care.
-
02
ICER to assess synthetic psilocybin therapy COMP360 for treatment-resistant depression, with public comments open through November 10, 2026
ICER will evaluate COMP360's clinical effectiveness and value for treatment-resistant depression, with public input now invited.
-
03
Sechsstündige intravenöse DMT-Infusion bei 29 gesunden Erwachsenen in einer kontrollierten Studie untersucht
A controlled study tested a six-hour intravenous DMT infusion in 29 healthy adults, focusing on prolonged dosing safety and tolerability.
-
04
Before European Approvals: Norway, Germany, Switzerland, the UK and Estonia Build Psychedelic Access Pathways at TAIP 2026
European access models are advancing before approvals, led by Norway's reimbursed ketamine pathway for depression and suicidal crisis.
-
05
MDA verursacht länger anhaltende Wirkungen und mehr Nebenwirkungen als MDMA in einer randomisierten Cross-over-Studie
A randomized crossover study found that MDA produced longer-lasting effects and more adverse events than MDMA.
-
06
Psilocybin PTSD evidence appeared first in an SEC filing, exposing how media, journals and registries show different levels of trial maturity
The analysis shows how SEC filings, trial registries, journals, and news coverage can convey sharply different stages of PTSD evidence.
-
07
FDA approval of psychedelics could drive an underground boom, requiring public health measures for risks and adverse events
Oregon data support planning for adverse events beyond regulated services, where most psychedelic use is likely to occur.
-
08
A history of magic mushrooms: Andy Letcher separates documented psilocybin history from European legends, colonial bias, and modern mythology
Historian Andy Letcher separates documented Mesoamerican mushroom use from weak claims about prehistoric European traditions.